199 related articles for article (PubMed ID: 38911540)
1. Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.
Park M; Kim JW
Toxicol Res; 2024 Jul; 40(3):335-348. PubMed ID: 38911540
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
3. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
Diesendruck Y; Benhar I
Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
Prabhu VV; Devaraj N
J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
[TBL] [Abstract][Full Text] [Related]
8. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.
Manso T; Kushwaha A; Abdollahi N; Duroux P; Giudicelli V; Kossida S
Front Immunol; 2023; 14():1129323. PubMed ID: 37215135
[TBL] [Abstract][Full Text] [Related]
10. Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies.
Olejarz W; Basak G
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136311
[TBL] [Abstract][Full Text] [Related]
11. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
12. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.
Raghani NR; Chorawala MR; Mahadik M; Patel RB; Prajapati BG; Parekh PS
Med Oncol; 2024 Jan; 41(2):51. PubMed ID: 38195781
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
[TBL] [Abstract][Full Text] [Related]
15. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
16. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract][Full Text] [Related]
17. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
Klener P; Etrych T; Klener P
Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
[TBL] [Abstract][Full Text] [Related]
18. Innovative Therapy, Monoclonal Antibodies and Beyond.
Di Nicola M; Apetoh L; Bellone M; Colombo MP; Dotti G; Ferrone S; Muscolini M; Hiscott J; Anichini A; Pupa SM; Braud F; Del Vecchio M
Cytokine Growth Factor Rev; 2017 Dec; 38():1-9. PubMed ID: 29029813
[TBL] [Abstract][Full Text] [Related]
19. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Wurz GT; Kao CJ; DeGregorio MW
Ther Adv Med Oncol; 2016 Jan; 8(1):4-31. PubMed ID: 26753003
[TBL] [Abstract][Full Text] [Related]
20. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors.
Aghanejad A; Bonab SF; Sepehri M; Haghighi FS; Tarighatnia A; Kreiter C; Nader ND; Tohidkia MR
Int J Biol Macromol; 2022 May; 207():592-610. PubMed ID: 35296439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
